

Recommendations for VoY CCG from York and Scarborough Medicines Commissioning Committee April 2016

	Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential cost impact
1	Paraldehyde 50% in olive oil enema 30ml	For treatment of epilepsy	Approved	Review of formulary status	As per Sheffield treatment guideline	Red	£32.25 per patient for 3 year treatment. Likely number of patients 1-2 per year.
2	Ulipristal	Uterine fibroids	Not approved	Await further cost effective evidence	Not commissioned	Black	Nil at present
3	Yasmin	Contraception	Approved only 3 rd line option	Not as cost effective as branded generics	3 rd line after cheaper branded generics	Green	No additional costs
4	Sodium chloride oral solution 1mmol/ml	Sodium supplementation/ replacement in neonates	Approved	Review of formulary status	As per current formulary status	Amber (specialist recommendation)	No new cost impact
5	Hydrocortisone rectal	Ulcerative colitis and other rectal / GI conditions	Approved	Review of formulary status	As per current formulary status	Amber (specialist recommendation)	No new cost impact
6	Prednisolone rectal	Ulcerative colitis and other rectal / GI conditions	Approved	Review of formulary status	As per current formulary status	Amber (specialist recommendation)	No new cost impact
7	Arachis oil enema	Faecal softener	Approved	Review of formulary status	As per current formulary status	Green	No new cost impact
8	Phosphate enema	Constipation	Approved	Review of formulary status	As per current formulary status	Green	No new cost impact

9	Sodium citrate enema	Constipation	Approved	Review of formulary status	As per current formulary status	Green	No new cost impact
10	Bowel cleansing agents e.g. Citramag	Resistant constipation	Approved	Review of formulary status	Confirmation of formulary status	Green	No new cost impact
11	Ursodeoxycholic acid	Itching and stones	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
12	Colestyramine	Itching or cholesterol	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
13	Methyldopa	Hypertension	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
14	Verapamil	Arrhythmias	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
15	Alfentanil injection	Palliative care	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
16	Methadone	Pain	Approved	Review of formulary status	Confirmation of formulary status	Red	No new cost impact
17	Capsacin cream	postherpetic neuralgia and diabetic neuropathy	Approved	Review of formulary status	Confirmation of formulary status	Green as per NICE guidance for neuropathic pain	No new cost impact
18	Carbimazole	Hyperthyroidism	Approved	Review of formulary status	Confirmation of formulary status	Green	No new cost impact
19	Propylthiouracil	Hyperthyroidism	Approved	Review of formulary status	Confirmation of formulary status	Green	No new cost impact

20	Hydrocortisone	Adrenal insufficiency	Approved	Review of formulary status	Confirmation of formulary status	Green	No new cost impact
21	Cabergoline	Parkinson's Disease; suppress lactation and hyperprolactinaemia	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
22	Diazoxide	chronic intractable hypoglycaemia	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
23	Liothyronine	Hypothyroidism	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
24	Cyproterone	Antiandrogen / precious puberty	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
25	Desmopressin	Diabetes insipidus	Approved	Review of formulary status	Confirmation of formulary status	Amber (specialist recommendation)	No new cost impact
26	Danazol	Endometriosis; Benign fibrocystic breast disease	Approved	Review of formulary status	Confirmation of formulary status	Amber specialist recommendation	No new cost impact
27	Lidocaine patches	Pain	Approved	Review of formulary status	Confirmation of formulary status	Red	No new cost impact – potentially cost saving

Additional comments:

- The palliative care list – last month all drugs included were referred to as approved as green: some drugs have now been classified as amber and are recommended to be approved as such.
- Emollients medal ranking – Fully approved.